Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VistaGen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
VistaGen Therapeutics and Baylor College of Medicine Enter into Agreement 12
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 13
VistaGen Therapeutics Enters Into Agreement With Celsis In Vitro Technologies 14
VistaGen Therapeutics Enters Into Research Agreement With Duke University 15
Licensing Agreements 16
BlueRock Therapeutics Enters into Licensing Agreement with VistaGen Therapeutics 16
VistaGen Therapeutics Enters into Licensing Agreement with University Health Network 17
VistaGen Therapeutics Enters Licensing Agreement with University Health Network 18
VistaGen Therapeutics Enters Into Licensing Agreement With McEwen Centre for Regenerative Medicine 19
Equity Offering 20
VistaGen Therapeutics Raises USD15 Million in Public Offering of Shares and Warrants 20
Vistagen Therapeutics Raises USD2.4 Million in Public Offering of Shares and Warrants 22
VistaGen Therapeutics Raises USD1 Million in Private Placement of Shares 24
VistaGen Therapeutics Raises USD1 Million in Private Placement 25
VistaGen Therapeutics Raises USD10 Million in Public Offering of Shares and Warrants 26
VistaGen Therapeutics Raises USD1.6 Million in Private Placement of Securities 28
VistaGen Therapeutics Completes First Tranche Of Private Placement Of Shares For US$0.025 Million 29
Debt Offering 30
VistaGen Therapeutics Raises USD3 Million in Private Placement of 10% Notes 30
VistaGen Therapeutics Raises USD1 Million in Private Placement of 10% Notes 31
VistaGen Therapeutics Inc – Key Competitors 32
VistaGen Therapeutics Inc – Key Employees 33
VistaGen Therapeutics Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 14, 2018: VistaGen Therapeutics announces fiscal 2019 first quarter financial results 35
Jun 26, 2018: VistaGen Therapeutics Announces Fiscal Year 2018 Financial Results 37
Feb 12, 2018: VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results 39
Nov 09, 2017: VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update 40
Aug 14, 2017: VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update 42
Jun 29, 2017: VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update 44
Feb 13, 2017: VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 46
Corporate Communications 48
Aug 21, 2017: VistaGen Therapeutics Expands VistaStem’s Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhD 48
Product News 49
07/10/2017: VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain 49
04/27/2017: VistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101′s Potential for Treating Neuropathic Pain 50
Product Approvals 52
Jan 03, 2018: VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder 52
Clinical Trials 53
Jun 13, 2018: VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101 53
Apr 05, 2018: VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder 54
Mar 19, 2018: VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101 55
Jan 29, 2018: VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder 56
Jan 22, 2018: VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets Investor Conference 58
Oct 26, 2017: VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder 59
Jun 22, 2017: VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101′s Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain 60
Jan 05, 2017: VistaGen Therapeutics to Present at Biotech Showcase 2017 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VistaGen Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
VistaGen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VistaGen Therapeutics and Baylor College of Medicine Enter into Agreement 12
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 13
VistaGen Therapeutics Enters Into Agreement With Celsis In Vitro Technologies 14
VistaGen Therapeutics Enters Into Research Agreement With Duke University 15
BlueRock Therapeutics Enters into Licensing Agreement with VistaGen Therapeutics 16
VistaGen Therapeutics Enters into Licensing Agreement with University Health Network 17
VistaGen Therapeutics Enters Licensing Agreement with University Health Network 18
VistaGen Therapeutics Enters Into Licensing Agreement With McEwen Centre for Regenerative Medicine 19
VistaGen Therapeutics Raises USD15 Million in Public Offering of Shares and Warrants 20
Vistagen Therapeutics Raises USD2.4 Million in Public Offering of Shares and Warrants 22
VistaGen Therapeutics Raises USD1 Million in Private Placement of Shares 24
VistaGen Therapeutics Raises USD1 Million in Private Placement 25
VistaGen Therapeutics Raises USD10 Million in Public Offering of Shares and Warrants 26
VistaGen Therapeutics Raises USD1.6 Million in Private Placement of Securities 28
VistaGen Therapeutics Completes First Tranche Of Private Placement Of Shares For US$0.025 Million 29
VistaGen Therapeutics Raises USD3 Million in Private Placement of 10% Notes 30
VistaGen Therapeutics Raises USD1 Million in Private Placement of 10% Notes 31
VistaGen Therapeutics Inc, Key Competitors 32
VistaGen Therapeutics Inc, Key Employees 33
VistaGen Therapeutics Inc, Subsidiaries 34
List of Figures
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VistaGen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10